Hi, my story is sort of simple, I developed Psoriasis after a bad case of Tonsilitus I had just after the birth of my 3rd child, a daughter who is 13 now, and have had a bit of a battle ever since, been prescribed various courses of creams and phototherapy (uvb and puva). These had various effects (puva worked the best). It hasn't stopped me doing the things i want to do apart from last year when I had 90% body coverage, including inside my ears and under my eyelids, at one point the pain in my knees and hips made me immobile for a few weeks, but thanks to my older two kids we got past that, and now I still have the (what seems to be permanent) patches, I do hope one day I will have no patches and always look on the bright side.

I now have a really supportive girlfriend who sees me and not just my skin also all my friends are very supportive too. I am lucky in that way.
i don't know anyone who has Psoriasis to talk to that knows what it feels like, that's why I joined this forum, to speak to people and make friends with other people with this skin complaint.

I'm not good at writing about stuff like this, so i apologise, but if you want to chat of have any advice or questions, I'd be really happy if you contact me, and if you have facebook you could add me there as well, thanks for reading

Davie

Ok folks,

How do I get photos on here . I have read all the help stuff, been to ikea for more instructions, recruited the help of children. But sadly nothing.

I have clicked on what I believe is the right button but get asked for a URL//

Do I need to find a host site first ?

Can I upload direct into a post ?

I am currently sitting on my potty sulking...


Thadius

My Turmeric Cure Story

This is the story of how the natural herb Turmeric is helping me to cure psoriasis. It has been proven time and time again that Turmeric can solve many problems in the field of health, from skin conditions, to joint pain and even cancer in many circumstances.

My story is a little different to most stories but you might find it interesting. It started 8 years ago, one day I noticed a patch of slightly dry skin on my knee, but as it was not really bothering me or very painful I really just ignored it. Since sometimes you can end up taking medicine and making things worse. A few weeks later I was walking outside and accidentally stepped on a nail; typically the nail was pointing up and pierced my foot. I was immediately told to go and have a tetanus shot as always as it is better to be safe than sorry. The medical centre advised me that a tetanus and polio combination shot was now the normal thing to have so I didn’t give it a second thought; I decided to have that shot. After all I didn’t want some nasty infection from that nail.

But a little while later I noticed that the shot was giving me side effects, and then I suffered a full blown psoriasis attack, I'm not sure at this stage if it was down to the immunization shot or not but it seems like an odd coincidence. My joints flared up with pain, terrible stiffness and sharp aching around the knees. My skin started to scale and thicken in places where the psoriasis started to flare up.

The worst part was my leg, my leg developed a cyst inside which had swollen and burst, leaking oil into my leg. The leg actually swollen up to the size of an elephant’s leg, it was massive and the doctor decides I should have a steroid shot to bring it down. I then spent the next few months trying various medications and eventually settled for methotrexate.

I have been on this medication now for eight years. But this only sedates the problem it doesn’t solve it, I still have plaque thickness and terrible redness formed by the psoriasis, I thought maybe I was going to just deal with it and resign myself to having this condition all of my life.

Then one day I found out about a man who had been taking Turmeric as a medicine, more specifically using it to cure his psoriasis skin condition. My first reaction was a little skeptical, but since there was nothing to lose I thought I might as well try it. So in August 2012 I started taking turmeric as a medication. I was amazed, in two weeks some of the patches of skin had vanished completely, and the worst parts of my elbows had been reduced down the last layer, I can see these clearing up completely within months.

The skin on my left leg has also been reduced in redness and will disappear soon fingers crossed. The added bonus of taking turmeric as a medicine, along with curing my terrible psoriasis, is that my once high blood pressure is now down to normal.

A great success story for turmeric as a medication.

Paul-Dee
Disclaimer
Nothing in this article should be construed as medical advice. Always check with your personal physician or licensed health care practitioner before making any significant modification in your diet or lifestyle, to insure that the ingredients or lifestyle changes are appropriate for your personal health condition and consistent with any medication you may be taking.

Advance abstract ahead of print as supplied by publisher.

Quote:

---

To gain further insight into the genetic architecture of psoriasis, we conducted a meta-analysis of 3 genome-wide association studies (GWAS) and 2 independent data sets genotyped on the Immunochip, including 10,588 cases and 22,806 controls.

We identified 15 new susceptibility loci, increasing to 36 the number associated with psoriasis in European individuals. We also identified, using conditional analyses, five independent signals within previously known loci. The newly identified loci shared with other autoimmune diseases include candidate genes with roles in regulating T-cell function (such as RUNX3, TAGAP and STAT3).

Notably, they included candidate genes whose products are involved in innate host defense, including interferon-mediated antiviral responses (DDX58), macrophage activation (ZC3H12C) and nuclear factor (NF)-κB signaling (CARD14 and CARM1).

These results portend a better understanding of shared and distinctive genetic determinants of immune-mediated inflammatory disorders and emphasize the importance of the skin in innate and acquired host defense.

Objective:
To investigate the relationship of excess and central adiposity with pediatric psoriasis severity.

Design, Setting, and Participants:
Multicenter, cross-sectional study of 409 psoriatic children. Psoriasis was classified as mild (worst Physician's Global Assessment score ≤3 with body surface area ≤10%) or severe (worst Physician's Global Assessment score ≥3 with body surface area >10%). Children were enrolled from 9 countries between June 19, 2009, and December 2, 2011.

Main Outcome Measures:
Excess adiposity (body mass index percentile) and central adiposity (waist circumference percentile and waist to height ratio).

Results:
Excess adiposity (body mass index ≥85th percentile) occurred in 37.9% of psoriatic children (n = 155) vs 20.5% of controls (n = 42) but did not differ significantly by severity. The odds ratio (95% CI) of obesity (body mass index ≥95th percentile) overall in psoriatic children vs controls was 4.29 (1.96-9.39) and was higher with severe (4.92; 2.20-10.99) than with mild (3.60; 1.56-8.30) psoriasis, particularly in the United States (7.60; 2.47-23.34, and 4.72; 1.43-15.56, respectively). Waist circumference above the 90th percentile occurred in 9.3% of the control (n = 19), 14.0% of the mild psoriasis (n = 27), and 21.2% of the of severe psoriasis (n = 43) participants internationally; this incidence was highest in the United States (12.0% [n = 13], 20.8% [16], and 31.1% [32], respectively). Waist to height ratio was significantly higher in psoriatic (0.48) vs control (0.46) children but was unaffected by psoriasis severity. Children with severe psoriasis at its worst, but mild at enrollment, showed no significant difference in excess or central adiposity from children whose psoriasis remained severe.

Conclusions:
Globally, children with psoriasis have excess adiposity and increased central adiposity regardless of psoriasis severity. The increased metabolic risks associated with excess and central adiposity warrant early monitoring and lifestyle modification.

Source: NO LINKS ALLOWED

A member contacted me to suggest a new thread about Skin Camouflage. There are a few threads where people mention they have problems with showing their skin in public, and as a result they are losing confidence. So I’m going to make this a sticky thread and you can add your tips to it.

Here are some I posted on another thread.

If you’re not sure about exposing your skin, use long sleeved shirts with the arms rolled up, you can always pull them down quick. Same applies to trouser legs.

If you have long hair tie it back with a scrunchie, when someone comes nearby let your hair down. For short hair wear a sun hat to cover your scalp and take it off when no one’s around.

Please add your tips to this thread.

Ok here we go....

I have tried to keep this brief and if there are any questions please, please ask.

I have left out the Sponsors name and the code reference to the product.

The product has been given to more than 2500 in other studies of psoriasis, rheumatoid arthritis, inflammatory bowl disease and dry eye.

I am one of 660 patients in 12 countries being asked to take part in the study because I have chronic plaque psoriasis. I am one of 50 patients in the UK. The study is over a period of 56 weeks.

I am currently in phase 3 of a mixed blind treatment, withdrawal and re-treatment study of 2 oral doses in subjects with moderate to severe plague psoriasis.

The product is a blocker of an enzyme called "Janus Kinase"' which acts like a gate into the cells of the immune system ( our body's defence against infection). By blocking the enzyme, the cells of the immune system are expected to produce fewer chemicals believed to cause psoriasis.

The study is looking at the good and bad effects. I attend a Hospital clinic every 4 weeks. I give several blood samples and have a full health scan including an inspection of my skin condition. Periodically I have full ECG etc. Apart from checking my vitals the study monitors blood, urine, my genes (DNA),RNA, proteins and metabolises.

During the study I am not allowed to use any other form of treatment or spend time in sunlight.

I keep a diary of my doses and I have a questionnaire at each clinic which asks about my mental and emotional state, if there are any restrictions on my work, study, sex life and general social being.

I took photos on the first day of my treatment ( I have no problems at anyone seeing them ) which when I work out how to upload etc.

The product is not a cure but it is a suppressor. At this moment in time ( week 44) my skin is 100% clear and yes I look sexy again I feel good about myself but not confident enough to go shopping in a mankini just yet.

I will give out more info as I progress into the extension study.

So for now folks..... There is hope x

Thadius

Hi all,

I am currently a volunteer carrying out clinical trials. The treatment form is oral and at present is running blind. This means some tablets are active and others are placebo. I nor the trial clinic know what treatment I am on and I have unique trial number so I am a blind subject to, if that makes sense.

My treatment began last year,(more details on my profile about severity etc), on day one I took photos of skin condition, yes they are available, so I could keep a record of my wishful thinking.

I am pleased to say that I am totally clear, not a spot, not a flake. I am 11 months into the trials and still more to go. I have details of the trials and will release as much as the clinic will allow. I feel at this point there are no restrictions but please be patient. I am not one for holding back

Thadius

So, it's xmas time coming up and I've just started a new job ish (4 months) when I am at work I wear jeans and a jumper so no one sees my skin. This is good but the xmas party is coming up and because no one has seen any of me I have no idea what to wear out. I know this might sound silly but does anyone know if I can just put a lil make up on my arms? It wouldnt only be for a few hours. I've gone threw my life not showing my legs (even in the summer time) so as annoying as it still is it's okay and I can always wear tights. My arms have been fine all my life really. I don't wanna think too much about it coz I will stress and that's obviously not what I want to do but I get so sad not even being able to go and shop for something nice to wear out. Sorry if this sounds lame but no one else understands

This is the PSUMMIT II result. PSUMMIT I, was first reported here: Stelara and Psoriatic Arhtritis Phase 3 data

Janssen Research & Development, LLC (Janssen) announced today new findings from PSUMMIT II, a Phase 3 investigational study that showed patients with active psoriatic arthritis, including those previously treated with one to five tumor necrosis factor (TNF) inhibitors, receiving the interleukin (IL)-12/23 inhibitor STELARA® (ustekinumab) demonstrated significant improvements in signs and symptoms of the disease.  Significantly more patients receiving either STELARA 45 mg or 90 mg achieved at least a 20 percent improvement in signs and symptoms according to American College of Rheumatology criteria (ACR 20) at week 24, the primary endpoint, than did patients receiving placebo regardless of background methotrexate use.  During a late-breaker session of PSUMMIT 1, the initial Phase 3 study, investigators will present 52-week data that showed improvement in efficacy of STELARA over time in treating signs and symptoms of the disease.  These data are being presented at the 2012 Annual Meeting of the American College of Rheumatology.  

In the Phase 3 Multicenter, Randomized, Double-blind, Placebo‑controlled trial of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis Including Those Previously Treated with Biologic Anti-TNF-alpha Agent(s) (PSUMMIT II) study, patients with active psoriatic arthritis despite treatment with disease-modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs) and/or anti-TNF-alpha therapy (not intended as a superiority or comparative claim versus TNF inhibitors) were randomized to receive subcutaneous STELARA 45 mg or 90 mg or placebo at weeks 0, 4 and then every 12 weeks.  At week 24, the primary endpoint was met as statistically significantly greater proportions of patients achieving ACR 20 responses (a standard measure of improvement in disease activity) were observed in patients receiving STELARA 45 mg (43.7 percent of patients) or STELARA 90 mg (43.8 percent of patients) compared with 20.2 percent of patients receiving placebo (P < 0.001 for both comparisons).  Among patients previously treated with TNF inhibitors, 36.7 percent of patients and 34.5 percent of patients receiving STELARA 45 mg or 90 mg, respectively, achieved ACR 20 at week 24 compared with 14.5 percent of patients receiving placebo (P = 0.006 for STELARA 45 mg, P = 0.011 for STELARA 90 mg).

"TNF inhibitors are the only approved biologic treatment option for psoriatic arthritis, but not all patients benefit from these currently available treatments," said Christopher Ritchlin, M.D., M.P.H., Professor of Medicine and Director of the Rheumatology Fellowship Program and the Clinical Immunology Research Center at the University of Rochester Medical Center, and lead study investigator.  "A biologic therapy with a different mechanism of action, like ustekinumab, which has shown benefit in the treatment of psoriatic arthritis in two Phase 3 studies, is exciting for the rheumatology community."

In PSUMMIT II, significantly greater proportions of patients receiving STELARA 45 or 90 mg achieved ACR 50 at week 24 compared with placebo (17.5 and 22.9 percent vs. 6.7 percent, P = 0.018 for STELARA 45 mg, P = 0.001 for STELARA 90 mg).  ACR 70 responses for both STELARA groups were greater, though not significantly, than for the placebo group at week 24.  Of patients with at least three percent body surface involvement of psoriasis at the start of PSUMMIT II, 51.3 percent and 55.6 percent of patients receiving STELARA 45 mg and 90 mg achieved at least a 75 percent improvement in psoriasis, respectively, as measured by the Psoriasis Area Severity Index (CASI 75), compared with five percent of patients receiving placebo (P < 0.001 for both comparisons).  Significant improvements from baseline to week 24 were also observed in physical function, as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI), in the STELARA 45 mg and 90 mg treatment groups compared with placebo-treated patients (P = 0.001 for STELARA 45 mg, P < 0.001 for STELARA 90 mg).

Similar proportions of patients experienced at least one adverse event (AE) through week 16, the placebo-controlled period, among those receiving STELARA 45 mg (63.1 percent), STELARA 90 mg (60.6 percent) and placebo (54.8 percent) with infections being the most common AE.  Serious AEs reported among the groups were: STELARA 45 mg (zero percent), STELARA 90 mg (1.0 percent) and placebo (4.8 percent).  No cases of tuberculosis (TB), opportunistic infections, major adverse cardiovascular events (MACE) or deaths occurred.  Through week 24, one serious infection due to complications of pre-existent interstitial lung disease was reported in the placebo group and one skin malignancy (squamous cell carcinoma in situ) occurred in the STELARA 90 mg group.

Improvement of Signs and Symptoms by STELARA in Patients with Active Psoriatic Arthritis: Week 52 Results of the Phase 3, Multicenter, Double-blind, Placebo-controlled PSUMMIT I Study

Findings from the Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis (PSUMMIT I) study are the focus of a late breaker oral presentation.  PSUMMIT I is evaluating the efficacy and safety of STELARA in patients with active psoriatic arthritis despite treatment with conventional therapy (anti-TNF-alpha naive) through 108 weeks.  Patients were randomized to receive subcutaneous STELARA 45 mg or 90 mg or placebo at weeks 0, 4 and then every 12 weeks.  At week 24, 42.4 percent and 49.5 percent of patients receiving STELARA 45 mg and 90 mg, respectively, achieved ACR 20, the primary endpoint, compared with 22.8 percent of patients receiving placebo (P < 0.001 for both comparisons).  Patients who qualified for early escape at week 16 were considered non-responders for the primary and major secondary analyses at week 24.  Following week 24 assessment, patients receiving STELARA 45 mg and 90 mg continued to receive every-12-week maintenance therapy, and placebo patients were crossed over to receive STELARA 45 mg induction (at weeks 24 and 28) and maintenance therapy every 12 weeks thereafter.  Observed data showed that signs and symptoms continued to increase between weeks 24 and week 52, with 55.7 percent, 60.3 percent and 65.2 percent of patients in the STELARA 45 mg, STELARA 90 mg and placebo crossover groups, respectively, demonstrating ACR 20 response.

"Long-term management of the signs and symptoms of disease is essential in the treatment of psoriatic arthritis, a systemic inflammatory disease that can be marked by chronic pain and dysfunction," said Arthur Kavanaugh, M.D., Professor of Medicine, and Director of the Center for Innovative Therapy at the University of California, San Diego, and co-principal investigator.  "These results build on previously reported 24-week data from the PSUMMIT I trial of ustekinumab and demonstrate efficacy and improvements in disease activity at one year for patients living with psoriatic arthritis."

ACR 50 and ACR 70 response rates increased from week 24 through week 52 among patients receiving STELARA maintenance therapy.  At week 24, among patients receiving STELARA 45 mg, 24.9 percent achieved ACR 50 compared with 8.7 percent in the placebo group (P < 0.001), which increased to 31.4 percent at week 52, and 12.2 percent achieved ACR 70 compared with 2.3 percent in the placebo group (P < 0.001) at week 24, which increased to 18 percent at week 52.  Similar changes were observed in the STELARA 90 mg group at week 24 as 27.9 percent achieved ACR 50 compared with 8.7 percent in the placebo group (P < 0.001), which increased to 37 percent at week 52, and 14.2 percent achieved ACR 70 compared with 2.3 percent in the placebo group (P < 0.001) at week 24, which increased to 21.2 percent at week 52.  Investigators also reported continued improvements in physical function and skin symptoms through the end of the study, with nearly half of patients demonstrating clinically meaningful change from baseline in HAQ-DI scores, and more than two-thirds of patients achieving PASI 75 at week 52.

Among study participants affected with enthesitis (inflammation of the entheses, the sites where tendons or ligaments attach to bone, n=425) or dactylitis (inflammation of the finger or toe, n=286) at baseline, patients receiving STELARA achieved clinically relevant improvements in both measures at week 24 and week 52.  At week 24, median percent changes in enthesitis scores (-42.9 for STELARA 45 mg and -50.0 for STELARA 90 mg) and dactylitis scores (-75.0 for STELARA 45 mg and -70.8 for STELARA 90 mg) were significantly higher than those seen for patients receiving placebo (P < 0.001 for all comparisons).  Improvements in enthesitis scores (-83.3, -74.2 and -87.5) and dactylitis scores (-100 in all patients) in the STELARA 45 mg, 90 mg and crossover groups, respectively, continued through week 52.

A similar proportion of patients experienced at least one AE or serious AE through week 16, the placebo-controlled period of PSUMMIT I.  Safety through week 52 was consistent with that observed during the placebo-controlled period between STELARA 45 mg and 90 mg groups in the incidence of AEs (66.8 percent and 64.7 percent, respectively) and serious AEs (5.9 percent and 3.4 percent, respectively).  No malignancies, cases of TB, opportunistic infections or deaths occurred through week 52.  Investigators reported three MACE in STELARA-treated patients in patients with multiple pre-existing cardiovascular risk factors.

Source: prnewswire.com

Cellceutix Corporation a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, reports that the Company has signed an agreement with a European Union (EU) clinical site for a Proof-of-Concept (PoC) trial of Prurisol™, the Company’s lead drug candidate for the treatment of psoriasis. The trial, a double blind study, is planned for the first quarter of 2013 and will include patient dosing over a 30-day period with follow up visits over the next 30 days.  Cellceutix decided on this protocol after discussions with pharmaceutical industry executives and believes this is the quickest path to evaluate the efficacy of Prurisol in humans with the objective of bringing it to market and creating greater shareholder value.

“Our laboratory research showed Prurisol to visually eliminate all traces of psoriatic tissue in human xenograft models in a short period of time.  We are very optimistic that the lab research will be replicated in a clinical setting,” said Leo Ehrlich, Chief Executive Officer at Cellceutix.  “There are more than 2 million people in the United States that suffer from psoriasis with few effective therapies available.  We believe that a new therapeutic bridging that gap could generate sales in excess of $1 billion annually, so we are naturally eager to see the effectiveness of Prurisol in human trials.  The pharmaceutical industry bases the value of a new drug on market size and the therapeutic benefit to patients, so we consulted with industry leaders on the most expeditious manner to give them that information.  A PoC trial in Europe was the answer.  The trials early next year are another milestone for us to continue to build value for our shareholders.”

Source: cellceutix.com

Other posts on Cellceutix / Prurisol
https://psoriasisclub.org/showthread.php?tid=121
https://psoriasisclub.org/showthread.php?tid=599

Hello. New member here. Minor skin P, not so minor P Arthritis. I'm just poking around trying to better understand what I have going on and ways to solve it. I am seeing a Rumatoidologist. I'm interested in the more obscure ways that this effects me and those with it. And for some reason, I am compelled to use this smilie.

I am coming up in bruises where some of my psoriasis is?

Is this normal?

Hello,
I am a 50 year old dentist from Finland and I was recently diagnosed with plaque psoriasis. I got strong cortisone salves from my doctor and they have helped me a lot. I have rashes only on my arms, scalp and ears. I find skin conditions very unpleasant and that doesn't help me very much.

Hey guys, Im new to this site so just wanna say Hi first of all

My doctor has given me Diprobase cream but I was just wondering about other ways I could keep my skin moisturised and what do you guys use. Does baby oil help or could you gimme another suggestion? I did buy baby oil the other day it was only £1 so if it doesnt work then im not too bothered.
Thanks

Background:
Psoriasis is associated with an atherogenic lipid profile but longitudinal changes in lipids around disease onset are unknown. The purpose of our study is to examine the effect of psoriasis onset on serum lipid profiles.

Methods:
We compared changes in lipid profiles in a population based incident cohort of 689 patients with psoriasis and 717 non-psoriasis subjects. All lipid measures performed 5 years before and after psoriasis incidence/index date were abstracted. Random-effects models adjusting for age, sex and calendar year were used to examine trends in lipid profiles.

Results:
There were significant declines in total cholesterol (TC) and low-density lipoprotein (LDL) levels during the 5 years before and after psoriasis incidence/index date in both the psoriasis and the non-psoriasis cohorts, with a greater decrease noted in the TC levels (p=0.022) and LDL (p=0.054) in the non-psoriasis cohort. High-density lipoprotein (HDL) levels increased significantly both before and after psoriasis incidence date in the psoriasis cohort. Triglyceride (TG) levels were significantly higher (p<0.001), and HDL levels significantly lower (p=0.013) in patients with psoriasis compared to non-psoriasis subjects. There were no differences in prescriptions for lipid lowering drugs between the two cohorts.

Conclusions:
Patients with psoriasis had a significant decrease in TC and LDL levels during the 5 years before psoriasis incidence. Higher mean TG and lower mean HDL levels were noted in the 5 years before psoriasis incidence. These changes are unlikely to be caused by lipid lowering treatment alone and require further exploration.

Source: NO LINKS ALLOWED

About 7 years ago I got shingles from the waist down on my right side. As you all probably know, shingles attacks the nerve endings. What is interesting is that everywhere the shingles broke out that was already covered by psoriasis, the psoriasis is now gone (light brown discoloration). Almost like the shingles stopped the signal to stop producing extra skin cells in that area. My Dermatologist doesn't think much of it but I think that some research should go into this. I would say about 20% of my upper thigh no longer has psoriasis.

New to forum and wanted to say hi.

I have had psoriasis for twenty years (now in my late 40's). I have been on Enbrel for 14 years and tried every lotion under the sun. Have it on about 30% of body. Mostly from the waist down and elbows.

I was diagnosed with psoriasis arthritis on my knee and that is how I came to taking Enrel. It does a nice job of reducing swelling and took care of terrible sclap problem but that is about it.

The expensive lotions help but , well they are expensive. I mostly use coconut oil. I by the 16oz jar for about $5. Can be greasy but I always wipe down with towel and apply several times a day.

I am an avid boater so in the early spring my exposed areas look real good but eventually it catches up then flakes so I am left with a nice tan and white skin were skin flakes off. Oh well. Tanning helps in winter for me

English research on the use of dimethylfumarates with Multiple Sclerosis. I do not have a subscription so I cannot see the whole Articles. Heard about these articles in a meeting on.... Psoriasis.
Because, what is Multiple Sclerosis ? Right, an immune disease. And what is psoriasis...?

If you have some boards that you don't view often, or you want less scrolling on your screen. You can shrink some boards by clicking the little icon in the top right corner of your chosen board.

Click images to enlarge